Conditioning prior to autologous hematopoietic stem cell transplant

Conditioning prior to autologous hematopoietic stem cell transplant is a procedural, preparative treatment phase rather than an intrinsic disease entity It affects the hematopoietic, immune, and reticuloendothelial systems in patients undergoing autologous transplantation, primarily for hematologic malignancies such as multiple myeloma and relapsed or refractory lymphoma, as well as select solid tumors and severe autoimmune disorders Defined by the delivery of high-dose, typically myeloablative ...

Conditioning prior to autologous hematopoietic stem cell transplant is a procedural, preparative treatment phase rather than an intrinsic disease entity

It affects the hematopoietic, immune, and reticuloendothelial systems in patients undergoing autologous transplantation, primarily for hematologic malignancies such as multiple myeloma and relapsed or refractory lymphoma, as well as select solid tumors and severe autoimmune disorders Defined by the delivery of high-dose, typically myeloablative chemotherapy with or without total body irradiation, its pathophysiologic intent is to maximize cytotoxic cytoreduction to eradicate residual disease and...

It affects the hematopoietic, immune, and reticuloendothelial systems in patients undergoing autologous transplantation, primarily for hematologic malignancies such as multiple myeloma and relapsed or refractory lymphoma, as well as select solid tumors and severe autoimmune disorders Unlike allogeneic conditioning, its primary objective is not host immunosuppression to prevent graft rejection, but rather profound tumor eradication followed by rescue and hematologic reconstitution using the patie...

It affects the hematopoietic, immune, and reticuloendothelial systems in patients undergoing autologous transplantation, primarily for hematologic malignancies such as multiple myeloma and relapsed or refractory lymphoma, as well as select solid tumors and severe autoimmune disorders

Defined by the delivery of high-dose, typically myeloablative chemotherapy with or without total body irradiation, its pathophysiologic intent is to maximize cytotoxic cytoreduction to eradicate residual disease and clear the bone marrow niche

Unlike allogeneic conditioning, its primary objective is not host immunosuppression to prevent graft rejection, but rather profound tumor eradication followed by rescue and hematologic reconstitution using the patient's previously harvested stem cells